Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102712 | 1.00 | MEN1 (0.34) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL9103896 | 0.95 | MEN1 (0.39) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL9103884 | 0.95 | MEN1 (0.39) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL13817508 | 0.93 | MEN1 (0.43) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| Hydrochloric Acid SCHEMBL9105769 | 0.93 | KMT2A (0.38) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| Hydrochloric Acid SCHEMBL9105755 | 0.93 | KMT2A (0.38) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL14473037 | 0.83 | GAA (0.37) | MAPT | |
| SCHEMBL17789411 | 0.81 | USP2 (0.47) | MEN1KMT2A | |
| SCHEMBL19982037 | 0.79 | CARM1 (0.46) | MEN1KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL9100739 | 0.78 | MEN1 (0.32) | MEN1KMT2AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | MEN1 482/4885KMT2A 552/4885CARM1 2836/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | MEN1 482/4885KMT2A 552/4885CARM1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.